XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

3 Months Ended

Mar. 31, 2016

Condensed Consolidated Financial Statements Detail [Abstract]

Accrued and other liabilities consisted of the following (in thousands):

	March 31, 2016		December 31, 2015
Accrued payroll and other benefits	$	1,573	$	2,156
Deferred rent		724		608
Accrued clinical trial costs		517		406
Accrued legal and accounting fees		511		517
Accrued incentive compensation		243		2,609
Accrued restructuring costs		138		459
Other		681		270
Total	$	4,387	$	7,025

Outstanding securities considered anti-dilutive

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

	Three Months Ended March 31,
	2016		2015
Common stock options and RSUs		10,704		8,756
Warrants for common stock		18,230		20,690
Total		28,934		29,446